Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 117 posts found.

biogen_austria_238

Biogen’s diroximel fumarate impresses at Phase 3 in relapsing multiple sclerosis

May 31, 2019
Medical Communications, Research and Development Biogen, diroximel fumarate, multiple sclerosis, pharma, relapsingg multiple sclerosis

New data for Biogen’s investigational therapy diroximel fumarate has been revealed at the Consortium of Multiple Sclerosis Centers (CMSC) in …

News

NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza

May 15, 2019
Research and Development Biogen, NHS England, Spinraza, UK, pharma, sma, spinal muscular atrophy

NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza. England’s National Health …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 22, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Biogen, Eisai, FDA, Merck, NICE, Pfizer, Roche, Sandoz

This week was a bad week for clinical trials. While the FDA put Roche and AbbVie’s multiple myeloma trial on …

News
eisa0008_web

Biogen and Eisai discontinue Phase 3 Alzheimer’s trial

March 21, 2019
Research and Development Alzheimer's, Biogen, CNS, Eisai, mental health

Biogen and Eisai have announced their decision to discontinue a Phase 3 trial looking into the efficacy and safety of …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Gilead, HIV, Novartis, Scott Gottlieb, top 10

HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ …

News

Biogen boosts ophthalmology portfolio with $800m acquisition of gene therapy firm Nightstar

March 4, 2019
Sales and Marketing Biogen, Nightstar, acquisition, pharma

Biogen has announced it has inked an agreement to acquire clinical-stage gene therapy firm Nightstar for a total value of …

News
shutterstock_292920209

UCB and Biogen’s lupus drug falls short at Phase 2b

October 24, 2018
Research and Development Biogen, Lupus, UCB, dapirolizumab pegol, pharma, systemic lupus erythematosus, trial falure

The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet …

News

Samsung and Bioepis launch third Humira biosimilar in Europe

October 17, 2018
Research and Development, Sales and Marketing Amgen, Biogen, Humira, Imraldi, Samusng Bioepis, pharma

Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of …

News
msd

MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar

October 8, 2018
Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis

American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …

News
14680814113_e81affc144_z_1

UK Health Secretary Matt Hancock rallies against ‘rip off’ pharma companies

September 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Matt Hancock, NICE, Vertex, pharma, pricing

British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business …

News
biogen_austria_238

NICE rejects Biogen’s spinal muscular dystrophy drug Spinraza after long delay

August 14, 2018
Manufacturing and Production, Sales and Marketing Biogen, NICE, Spinraza, UK, pharma, spinal muscular dystrophy

UK watchdog NICE has rejected Biogen’s spinal muscular dystrophy drug Spinraza (nusinersen) over cost concerns, denying patients the only available …

News
ptc

PTC Therapeutics’ results in SMA has Biogen nervous

June 19, 2018
Manufacturing and Production, Research and Development Biogen, PTC Therapeutics, biotech, drugs, pharma, pharmaceutical

Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that …

News
biogen_idec_hillerod_2008

Biogen boosts pipeline with $1bn Ionis deal

April 23, 2018
Sales and Marketing Biogen, Ionis, Spinraza, biotech, drugs, pharma, pharmaceutical

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …

News
humira_abbott__4

Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar

April 6, 2018
Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma

Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …

News
biology-think-networking-physiology-brain-anatomy-2676370

Pfizer begins sell-off, shedding CNS drug to Biogen for $590m

March 13, 2018
Manufacturing and Production, Sales and Marketing Biogen, CNS, Pfizer, biotech, drugs, pharma, pharmaceutical

Pfizer’s decision to back out of the neuroscience space was a strategic move that send shudders through the entire industry, …

News
The Gateway to Local Adoption Series

Latest content

Stage4You encourages stage 4 bowel cancer patients to prioritise mental health ahead of Bowel Cancer Awareness Month

March 26, 2026

Scotland starts newborn screening for SMA

March 26, 2026

Secarna appoints Jens Holstein and Richard Mark Engelhard to new Advisory Board

March 25, 2026

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory

March 25, 2026

ReproNovo appoints Mark Altmeyer as Chairman of the Board

March 24, 2026